Vanda Pharmaceuticals Inc. VNDA
3.67 USD -0.21 (-5.41%)
Nov 5, 2026, 12:14 PM EST
3.66 Day range 3.88
3.64 52-week range 9.94
- YTD
- -58.39%
- 1 year
- -17.34%
News
prnewswire.com Vanda Pharmaceuticals Announces Participation at November 2026 Investor Conferences WASHINGTON, Nov. 3, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in November…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session. The market value of their outstanding shares is at $1.7 billion. Glaukos (NYSE:GKOS) stock rose 15.75%…
benzinga.com Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.
seekingalpha.com Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript Vanda Pharmaceuticals Inc. (VNDA) Q3 2026 Earnings Call Transcript
marketbeat.com Vanda Pharmaceuticals Q3 Earnings Call Highlights Vanda Pharmaceuticals NASDAQ: VNDA reported third-quarter revenue growth of 24% from a year earlier, supported by higher Fanapt sales and a sharp sequential increase in HETLIOZ revenue tied partly to…
zacks.com Vanda Pharmaceuticals (VNDA) Reports Q3 Loss, Tops Revenue Estimates Vanda Pharmaceuticals (VNDA) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to a loss of $0.38 per share a year ago.
benzinga.com Vanda Pharma Q3 2026 Earnings Call Transcript Vanda Pharma (NASDAQ:VNDA) reported third-quarter financial results on Wednesday. The transcript from the company’s third-quarter earnings call has been provided below.Benzinga APIs provide real-time…
benzinga.com Vanda Pharma Q3 EPS $(0.37) Beats $(0.68) Estimate, Sales $69.815M Beat $69.202M Estimate Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(0.37) per share which beat the analyst consensus estimate of $(0.68) by 45.59 percent. This is a 2.63 percent increase over losses of $(0.38)…
prnewswire.com Vanda Pharmaceuticals Reports Third Quarter 2026 Financial Results Q3 2026 Total Revenues increased 24% to $69.8 million compared to Q3 2025 and 38% compared to Q2 2026 Q3 2026 Total Operating Expenses decreased by 18% to $93.3 million compared to Q2 2026 Announced…
benzinga.com Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released results from its Phase 3 trial evaluating Nereus, an oral therapy aimed at preventing vomiting associated with GLP-1 receptor agonist treatments.
benzinga.com Vanda Pharmaceuticals Targets Major GLP-1 Market Challenge with Positive Trial Outcomes Vanda Pharmaceuticals reports positive Phase 3 results for Nereus, demonstrating reduced vomiting linked to GLP-1 receptor agonist therapy.
benzinga.com Vanda Pharmaceuticals Announces Phase III Study Results Showing Significant Reduction In GLP-1 Therapy-Associated Vomiting With NEREUS NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomitingKey ResultsAny vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27%…
prnewswire.com Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting NEREUS™ significantly reduced semaglutide induced vomiting including frequent multi-day and extreme vomiting Key Results Any vomiting (primary) 43.0% (61/142) vs 58.5% (96/164) placebo (p=0.006); 27%…
prnewswire.com Vanda Pharmaceuticals to Announce Third Quarter 2026 Financial Results on October 28, 2026 Conference Call and Webcast to Follow WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the third quarter 2026 on…
benzinga.com Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) on Wednesday shared an update regarding its clinical development pipeline.
benzinga.com Vanda Pharmaceuticals Says Experimental Anxiety Treatment Misses Primary Endpoint Vanda Pharmaceuticals announced its Phase 3 trial for VQW-765 failed to meet primary endpoints for treating acute social anxiety disorder.
gurufocus.com Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development ProgramPR NewswireWASHINGTON, Oct. 14, 2026Phase III clinical study of VQW-765 in adults w
reuters.com Vanda says anxiety drug failed main goal of late-stage study, puts program on hold Vanda says anxiety drug failed main goal of late-stage study, puts program on hold
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) stock rose 13.3% to $0.55 during Wednesday's after-market session. Impact BioMedical (AMEX:IBO) stock rose 10.77% to $3.77. The company's market cap…- benzinga.com Vanda Pharmaceuticals' Phase III Clinical Study Of VQW-765 In Adults With Social Anxiety Disorder Did Not Meet Its Primary Endpoint; VQW-765 Was Safe And Well-Tolerated Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpointConsistent with prior studies, VQW-765 was safe and well toleratedWASHINGTON, Oct. 14, 2026…
prnewswire.com Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14,…
defenseworld.net Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as “Buy” by HC Wainwright Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday,…
benzinga.com HC Wainwright & Co. Reiterates Buy on Vanda Pharmaceuticals, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and maintains $20 price target.
gurufocus.com Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual MeetingPR NewswireWASHINGTON, Oct. 2, 2026WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharma
prnewswire.com Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being…
benzinga.com Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.
prnewswire.com Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022) 60% of HETLIOZ ® treated participants shifted sleep at least 30 minutes earlier, compared…
benzinga.com Oppenheimer Initiates Coverage On Vanda Pharmaceuticals with Outperform Rating, Announces Price Target of $10 Oppenheimer analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Outperform rating and announces Price Target of $10.
prnewswire.com Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the following upcoming investor conferences in…
benzinga.com Vanda Pharmaceuticals Receives EMA Orphan Designation For Imsidolimab For The Treatment Of Generalized Pustular Psoriasis The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP.This marks the…
prnewswire.com Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European…
gurufocus.com NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. NEREUS⢠Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. PR Newswire WASHI
prnewswire.com NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C. WASHINGTON, Aug. 22, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced that the NEREUS™ branded No. 47 entry from Rahal Letterman Lanigan Racing, driven by Mick…- benzinga.com B. Riley Securities Reiterates Buy on Vanda Pharmaceuticals, Lowers Price Target to $12 B. Riley Securities analyst Madison El-Saadi reiterates Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $17 to $12.
- benzinga.com HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $20 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $21 to $20.
- benzinga.com Vanda Pharma Q2 EPS $(1.04) Misses $(0.59) Estimate, Sales $50.529M Miss $61.925M Estimate Vanda Pharma (NASDAQ:VNDA) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.59) by 76.27 percent. This is a 126.09 percent decrease over losses of…
benzinga.com Vanda Pharmaceuticals Affirms FY2026 Sales Guidance of $240.000M-$290.000M vs $262.154M Est Vanda Pharmaceuticals (NASDAQ:VNDA) affirms FY2026 sales outlook from $240.000 million-$290.000 million to $240.000 million-$290.000 million vs $262.154 million estimate.- benzinga.com Vanda Pharmaceuticals Announces European Medicines Agency Adopts Positive Opinion For Orphan Drug Designation Of Imsidolimab For Generalized Pustular Psoriasis This marks the first time the EMA has granted orphan drug designation recognition for a drug to treat GPP in the European Union (EU). GPP is a severe, chronic, and potentially life-threatening…
- benzinga.com Vanda Pharma Says FDA Grants Rare Pediatric Disease Designation To VCA-894A For Treatment Of Charcot-Marie-Tooth Disease, Axonal, Type 2S Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to VCA-894A, Vanda's investigational…
- benzinga.com Vanda Pharmaceuticals Receives Japanese Orphan Drug Designation For Imsidolimab In Generalized Pustular Psoriasis Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to imsidolimab, a high‑affinity…
- benzinga.com HC Wainwright & Co. Maintains Buy on Vanda Pharmaceuticals, Lowers Price Target to $21 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy and lowers the price target from $24 to $21.
benzinga.com Earnings Scheduled For May 6, 2026 - benzinga.com Vanda Pharmaceuticals' NEREUS Now Commercially Available Throughout U.S. To Prevent Vomiting Induced By Motion In Adults Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that NEREUS™ (tradipitant) is now commercially available across the United States for the prevention of vomiting induced by motion in…
- benzinga.com Vanda Pharma Highlights Legislative Proposal Contained In FDA's FY 2027 Congressional Budget Justification; Proposal Will Eliminate Simple Statutory Requirement That FDA Must Review NDA Within 180 Days Of Filing Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today highlighted a legislative proposal contained in the FDA's FY 2027 Congressional Budget Justification.The proposal would eliminate the simple…
benzinga.com Vanda Pharmaceuticals Announces Initiation Of The Thetis Study, A Clinical Trial Of NEREUS For The Prevention Of Vomiting Induced By GLP-1 Receptor Agonists; Topline Results From Thetis Study Expected By Q4 2026; Phase 2 Study Succeeded And Met Its Primary Endpoint Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced the initiation of Thetis, a clinical trial evaluating NEREUS™ (tradipitant) for the prevention of vomiting in patients receiving…- benzinga.com Vanda Pharmaceuticals Advocates For Stronger FDA Measures To Accelerate Shift From Animal Testing To Human-Relevant Methods Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA), a leader in innovative drug development and a vocal advocate for reducing unnecessary animal testing, today voiced serious concerns over the U.S.…
benzinga.com This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday Top Wall Street analysts changed outlook on top names. See analyst ratings page for full view. EQIX stock initiated with Outperform rating.- benzinga.com Truist Securities Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces Price Target of $18 Truist Securities analyst Les Sulewski initiates coverage on Vanda Pharmaceuticals (NASDAQ:VNDA) with a Buy rating and announces Price Target of $18.
benzinga.com FDA Grants Vanda Pharma's Request For Formal Evidentiary Public Hearing To Review CDER Proposal To Refuse Approval Of sNDA For HETLIOZ In Treatment Of Jet Lag Disorder Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced that the U.S. Food and Drug Administration (FDA) has granted the company's request for a formal evidentiary public hearing to review…
benzinga.com Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug Vanda stock climbs after the FDA approves Bysanti for bipolar disorder and schizophrenia and reviews rare skin disease treatment.